DexCom, Inc. (DXCM) Shares Sold by Commonwealth Equity Services Inc

Commonwealth Equity Services Inc trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 23.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,082 shares of the medical device company’s stock after selling 1,272 shares during the quarter. Commonwealth Equity Services Inc’s holdings in DexCom were worth $199,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of DXCM. Advisor Group Inc. raised its holdings in DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after acquiring an additional 837 shares during the period. IFP Advisors Inc raised its holdings in DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after acquiring an additional 568 shares during the period. Toronto Dominion Bank raised its holdings in DexCom by 251.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock valued at $178,000 after acquiring an additional 2,608 shares during the period. Janney Montgomery Scott LLC raised its holdings in DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after acquiring an additional 250 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after acquiring an additional 354 shares during the period.

DexCom, Inc. (NASDAQ DXCM) opened at $58.00 on Wednesday. DexCom, Inc. has a 52-week low of $42.62 and a 52-week high of $88.80. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.

Several research analysts have weighed in on DXCM shares. TheStreet cut shares of DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. ValuEngine raised shares of DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Wedbush reissued a “buy” rating and issued a $76.00 price target on shares of DexCom in a report on Wednesday, October 4th. Robert W. Baird reissued a “hold” rating and issued a $79.00 price target on shares of DexCom in a report on Sunday, September 10th. Finally, Barclays started coverage on shares of DexCom in a report on Friday, September 15th. They issued an “equal weight” rating and a $76.00 price target on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $70.69.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $69.81, for a total transaction of $101,224.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the sale, the executive vice president now owns 65,049 shares in the company, valued at approximately $2,915,496.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,954 shares of company stock worth $2,266,296. Company insiders own 1.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/06/dexcom-inc-dxcm-shares-sold-by-commonwealth-equity-services-inc.html.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit